Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)
Papillomavirus Infections
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 6,000 (planned)
- Started
- Jun 26, 2019
- Main results expected
- Mar 31, 2028
- Fully finished
- Nov 30, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Stage I: Combined Incidence of HPV 31-, 33-, 45-, 52-, and 58-related 12-month Persistent Infection
Measured over: 1 month post vaccination 3 (Month 7) up to Month 30
Stage I: Geometric Mean Titers to HPV Types 6, 11, 16, and 18 Antibodies
Measured over: 1-month post vaccination 3 (Month 7)
Stage I: Percentage of Participants Who Report at Least 1 Solicited Injection-site Adverse Event
Measured over: up to 8 days post any vaccination
Stage I: Percentage of Participants Who Report at Least 1 Solicited Systemic Adverse Event
Measured over: up to 30 days post any vaccination
Stage I: Percentage of Participants Who Experience at Least 1 Serious Adverse Event (SAE)
Measured over: Day 1 up to approximately Month 30
Stage II: Combined Incidence of HPV 31-, 33-, 45-, 52-, and 58-related CIN 2/3, AIS, and cervical cancer
Measured over: Month 7 up to Month 90
Stages I/II: Percentage of Participants Who Experience at Least 1 Serious Adverse Event (SAE)
Measured over: Day 1 up to approximately Month 90
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03998254 · record last updated 2026-09-01 · checked 2026-11-09 15:47 UTC